Heartland Bank & Trust Co Acquires Shares of 21,291 Pfizer Inc. (NYSE:PFE)

Heartland Bank & Trust Co acquired a new position in Pfizer Inc. (NYSE:PFE) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 21,291 shares of the biopharmaceutical company’s stock, valued at approximately $596,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Gilbert & Cook Inc. lifted its stake in shares of Pfizer by 3.8% in the 4th quarter. Gilbert & Cook Inc. now owns 25,651 shares of the biopharmaceutical company’s stock valued at $738,000 after purchasing an additional 945 shares during the period. NEOS Investment Management LLC raised its holdings in Pfizer by 34.8% in the fourth quarter. NEOS Investment Management LLC now owns 80,004 shares of the biopharmaceutical company’s stock worth $2,303,000 after purchasing an additional 20,651 shares in the last quarter. Peapack Gladstone Financial Corp lifted its position in Pfizer by 13.7% during the fourth quarter. Peapack Gladstone Financial Corp now owns 592,714 shares of the biopharmaceutical company’s stock valued at $17,064,000 after buying an additional 71,514 shares during the period. Nicholas Company Inc. bought a new stake in shares of Pfizer during the 4th quarter valued at $6,464,000. Finally, Belpointe Asset Management LLC grew its position in shares of Pfizer by 21.3% in the 4th quarter. Belpointe Asset Management LLC now owns 105,245 shares of the biopharmaceutical company’s stock worth $3,030,000 after buying an additional 18,507 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. UBS Group upped their price target on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Wells Fargo & Company lifted their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Finally, Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Price Performance

NYSE PFE opened at $28.94 on Tuesday. Pfizer Inc. has a one year low of $25.20 and a one year high of $34.11. The stock has a 50-day moving average of $29.29 and a 200 day moving average of $28.30. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The company has a market capitalization of $163.96 billion, a price-to-earnings ratio of -482.25, a PEG ratio of 1.27 and a beta of 0.68.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the previous year, the business posted $0.67 earnings per share. On average, sell-side analysts forecast that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.